Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry

Leigh Turner; Paul Knoepfler

doi:10.1016/j.stem.2016.06.007

Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry

Leigh Turner, Paul Knoepfler

Center for Bioethics

Research output: Contribution to journal › Comment/debate › peer-review

267 Scopus citations

Abstract

Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace.

Original language	English (US)
Pages (from-to)	154-157
Number of pages	4
Journal	Cell Stem Cell
Volume	19
Issue number	2
DOIs	https://doi.org/10.1016/j.stem.2016.06.007
State	Published - Aug 4 2016

Bibliographical note

Publisher Copyright:
© 2016 Elsevier Inc.

Access

10.1016/j.stem.2016.06.007

OpenUrl availability

Full text

Cite this

@article{ec65a33fee74479db5d01287131d565e,

title = "Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry",

abstract = "Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace.",

author = "Leigh Turner and Paul Knoepfler",

note = "Publisher Copyright: {\textcopyright} 2016 Elsevier Inc.",

year = "2016",

month = aug,

day = "4",

doi = "10.1016/j.stem.2016.06.007",

language = "English (US)",

volume = "19",

pages = "154--157",

journal = "Cell Stem Cell",

issn = "1934-5909",

publisher = "Cell Press",

number = "2",

}

TY - JOUR

T1 - Selling Stem Cells in the USA

T2 - Assessing the Direct-to-Consumer Industry

AU - Turner, Leigh

AU - Knoepfler, Paul

PY - 2016/8/4

Y1 - 2016/8/4

N2 - Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace.

AB - Direct-to-consumer marketing of unapproved stem cell interventions is a well-known phenomenon in countries with lax medical regulations. However, an examination of Internet-based marketing claims revealed widespread promotion of such interventions by businesses based in the United States. Such commercial activity suggests that regulatory agencies must better oversee this marketplace.

UR - http://www.scopus.com/inward/record.url?scp=84978493321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978493321&partnerID=8YFLogxK

U2 - 10.1016/j.stem.2016.06.007

DO - 10.1016/j.stem.2016.06.007

M3 - Comment/debate

C2 - 27374789

AN - SCOPUS:84978493321

SN - 1934-5909

VL - 19

SP - 154

EP - 157

JO - Cell Stem Cell

JF - Cell Stem Cell

IS - 2

ER -

Selling Stem Cells in the USA: Assessing the Direct-to-Consumer Industry

Abstract

Bibliographical note

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this